In contrast to CARES, FAST found that treatment with febuxostat was not associated with an increase in cardiovascular or all-cause death compared with allopurinol in patients with gout.
Burden and progression of coronary atherosclerosis was found to be worsened in non-obese patients with rheumatoid arthritis and low vs high LDL levels.
Anticoagulants, antiplatelets, and thrombolytics for the treatment and/or prophylaxis of venous and arterial thrombosis.
Researchers determined the effect of disease-modifying antirheumatic drug therapy on patients with early rheumatoid arthritis with cardiovascular disease.
Gout was not found to be associated with increased risk for cardiovascular complications in patients with peripheral artery disease.
Study authors reviewed the evidence on the effectiveness of low-dose aspirin in the primary prevention of cardiovascular disease in systemic autoimmune rheumatic diseases.
Researchers examined whether a disease activity tool and the presence of carotid plaques can predict cardiovascular events, independent of traditional risk factors, in psoriatic arthritis.
Inhibition of sclerostin with romosozumab may increase cardiovascular risk.
Researchers identified carotid plaques as predictors of cardiovascular events in patients with rheumatoid arthritis.
Researchers evaluated the association between allopurinol use and mortality in patients with gout.